Aim: To better understand the current treatment pattern and glycemic control status in Chinese adults with T2DM.

Methods: A retrospective study was conducted among adult T2DM patients using electronic medical records from 2015 to 2019 in Tianjin, a metropolis in Northern China.

Results: From 2015 to 2019, a total of 312,203 patients from 75 hospitals were included, with mean age of 61.9 years old and BMI 26.1 kg/m2. HbA1c decreased from 8.2% to 7.9% with the percentages of HbA1c <7% increased from 28.1% to 33.7% (P<0.001). A growing proportion treated with basal insulin and GLP-1RA ± basal insulin was seen while the proportion of premixed insulin decreased (P<0.001). 44.0% of the subjects were treated with OAD only and the most frequently used OADs were α-glucosidase inhibitor (55.7%) and metformin (47.0%). The percentages of cardiovascular risk factors and macrovascular events including hypertension, dyslipidemia, obesity, cardiovascular disease and stroke were increased each year (P<0.001). During 2015-2019, 27.7% and 40.3% of the population had FPG<7 mmol/L and PPG<10 mmol/L, respectively, while 46.1% of them had both FPG ≥ 7 and PPG ≥10 mmol/L.

Conclusion: From 2015 to 2019, an increasing proportion of T2DM population achieved HbA1c target, reflecting the potential optimized treatment concept and regimen. Meanwhile, there is still room to improve the holistic management of T2DM in China for a better patient outcome.


L.Chen: None. L.Kang: Employee; Sanofi China. M.Li: None. Q.Zhang: None. Y.Fan: None. X.Liu: None. M.Zhang: Employee; Sanofi China. G.Wu: Employee; Sanofi China. M.Wu: Employee; Sanofi China. Q.Huang: Employee; Sanofi China. Y.Han: Employee; Sanofi China.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at